These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24225331)

  • 41. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
    Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
    Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.
    Johnson SK; Heuck CJ; Albino AP; Qu P; Zhang Q; Barlogie B; Shaughnessy JD
    Int J Hematol; 2011 Oct; 94(4):321-333. PubMed ID: 22002477
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Established and Novel Prognostic Biomarkers in Multiple Myeloma.
    Bustoros M; Mouhieddine TH; Detappe A; Ghobrial IM
    Am Soc Clin Oncol Educ Book; 2017; 37():548-560. PubMed ID: 28561668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.
    Muchtar E; Magen H; Gertz MA
    Leuk Lymphoma; 2017 Jun; 58(6):1283-1296. PubMed ID: 27734720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma.
    Zanwar S; Kumar S
    Leuk Lymphoma; 2021 Dec; 62(13):3087-3097. PubMed ID: 34304677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-risk multiple myeloma: Redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy.
    Rees MJ; Kumar S
    Am J Hematol; 2024 Aug; 99(8):1560-1575. PubMed ID: 38613829
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disturbed MAPK pathway in early bilateral testicular extramedullary relapse of multiple myeloma.
    Huang HF; Xu J; Xu AS; Wan XY; Chen L; Fan FJ; Zhang B; Tang L; Chen WX; Sun X; Ai LS; Hou J; Sun CY; Hu Y
    Leuk Res; 2020 Aug; 95():106403. PubMed ID: 32569928
    [No Abstract]   [Full Text] [Related]  

  • 49. Race-based differences in routine cytogenetic profiles of patients with multiple myeloma.
    Blue BJ; Luo S; Sanfilippo KM; Ganti A; Gumbel J; O'Brian K; Carson KR
    Br J Haematol; 2017 Jan; 176(2):322-324. PubMed ID: 26887893
    [No Abstract]   [Full Text] [Related]  

  • 50. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis.
    Soliman AM; Das S; Teoh SL
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299097
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The molecular characterization and clinical management of multiple myeloma in the post-genome era.
    Zhou Y; Barlogie B; Shaughnessy JD
    Leukemia; 2009 Nov; 23(11):1941-56. PubMed ID: 19657360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A rational approach to functional high-risk myeloma.
    Gay F; Bertuglia G; Mina R
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):433-442. PubMed ID: 38066896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiple myeloma with central nervous system relapse.
    Egan PA; Elder PT; Deighan WI; O'Connor SJM; Alexander HD
    Haematologica; 2020 Jul; 105(7):1780-1790. PubMed ID: 32414852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myeloma Is Not a Single Disease.
    Lonial S; Nooka AK
    J Oncol Pract; 2016 Apr; 12(4):287-92. PubMed ID: 27072380
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma.
    Mithraprabhu S; Reynolds J; Turner R; Quach H; Horvath N; Kerridge I; Kalff A; Bergin K; Hocking J; Yuen F; Khong T; Durie BM; Spencer A
    Blood Cancer J; 2023 Feb; 13(1):25. PubMed ID: 36781844
    [No Abstract]   [Full Text] [Related]  

  • 56. Approach to High-Risk Multiple Myeloma.
    Chen X; Varma G; Davies F; Morgan G
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):497-510. PubMed ID: 38195306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Cytogenetic and molecular prognostic factors for multiple myeloma].
    Nihon Rinsho; 2016 Jul; 74 suppl 5():283-7. PubMed ID: 30615372
    [No Abstract]   [Full Text] [Related]  

  • 58. The biological features of multiple myeloma.
    Michaeli J; Choy CG; Zhang X
    Cancer Invest; 1997; 15(1):76-84. PubMed ID: 9028393
    [No Abstract]   [Full Text] [Related]  

  • 59. International Myeloma Working Group recommendations for global myeloma care.
    Ludwig H; Miguel JS; Dimopoulos MA; Palumbo A; Garcia Sanz R; Powles R; Lentzsch S; Ming Chen W; Hou J; Jurczyszyn A; Romeril K; Hajek R; Terpos E; Shimizu K; Joshua D; Hungria V; Rodriguez Morales A; Ben-Yehuda D; Sondergeld P; Zamagni E; Durie B
    Leukemia; 2014 May; 28(5):981-92. PubMed ID: 24177258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes.
    Tanguay M; Dagenais C; LeBlanc R; Ahmad I; Claveau JS; Roy J
    Curr Oncol; 2023 May; 30(6):5214-5226. PubMed ID: 37366879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.